(Z)-1-(3-nitrophenyl)ethylidenehydrazine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (Z)-1-(3-nitrophenyl)ethylidenehydrazine
• 化学式: C8H9N3O2
• 分子量: 179.18
• InChiKey: CUEIIDSEGRHPOU-POHAHGRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• NOVEL 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES
  申请人：SANWA KAGAKU KENKYUSHO CO., LTD.

  公开号：EP3072884A1

  公开（公告）日：2016-09-28

  The object of the present invention is to provide a compound having an antagonistic action against µ-opioid receptors, which causes less side effects and thus is highly safe. A compound represented by the general formula (I), or a pharmacologically acceptable salt thereof: wherein R1 and R2 are the same or different, and each represents a hydrogen atom or a halogen atom, provided that R1 and R2 are not simultaneously halogen atoms, R3 represents a C1-C3 alkyl group or a vinyl group, and R4 represents the formula (II): wherein R5 represents a hydroxy group or a C1-C3 alkoxy group, and R6 and R7 are the same or different, and each represents a hydrogen atom or a halogen atom; or the formula (III): wherein Ring A represents a halogen atom(s)-substituted C5-C7 cycloalkyl group which is optionally substituted by a C1-C3 alkoxy group, or a halogen atom(s)-substituted 5- to 7-membered saturated heterocyclic group.

  本发明的目的是提供一种对μ-阿片受体具有拮抗作用的化合物，该化合物的副作用较小，因此安全性高。 通式(I)代表的化合物或其药理学上可接受的盐： 其中 R1 和 R2 相同或不同，各自代表氢原子或卤素原子，但 R1 和 R2 不能同时代表卤素原子、 R3 代表 C1-C3 烷基或乙烯基，以及 R4 代表式 (II)： 其中 R5 代表羟基或 C1-C3 烷氧基，R6 和 R7 相同或不同，且各自代表氢原子或卤素原子； 或式 (III)： 其中环 A 代表任选被 C1-C3 烷氧基取代的卤原子取代的 C5-C7 环烷基或卤原子取代的 5-7 元饱和杂环基。
• NOVEL 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSE
  申请人：SANWA KAGAKU KENKYUSHO CO., LTD.

  公开号：US20160280645A1

  公开（公告）日：2016-09-29

  The object of the present invention is to provide a compound having an antagonistic action against μ-opioid receptors, which causes less side effects and thus is highly safe. A compound represented by the general formula (I), or a pharmacologically acceptable salt thereof: wherein R 1 and R 2 are the same or different, and each represents a hydrogen atom or a halogen atom, provided that R 1 and R 2 are not simultaneously halogen atoms, R 3 represents a C 1 -C 3 alkyl group or a vinyl group, and R 4 represents the formula (II): wherein R 5 represents a hydroxy group or a C 1 -C 3 alkoxy group, and R 6 and R 7 are the same or different, and each represents a hydrogen atom or a halogen atom; or the formula (III): wherein Ring A represents a halogen atom(s)-substituted C 5 -C 7 cycloalkyl group which is optionally substituted by a C 1 -C 3 alkoxy group, or a halogen atom(s)-substituted 5- to 7-membered saturated heterocyclic group.
• US9663463B2
  申请人：——

  公开号：US9663463B2

  公开（公告）日：2017-05-30